利用新型生物标志物数据构建和评估外周动脉疾病相关重大不良肢体事件的预测模型
本研究基于前瞻性招募的569例外周动脉疾病(PAD)患者队列,利用人口学、临床及三种生物标志物(NT-proBNP、FABP3、FABP4)数据,训练三种机器学习模型预测3年PAD相关重大不良肢体事件(MALE)。XGBoost模型表现最佳,测试集AUROC为0.88(95%CI 0.84-0.94),独立验证队列AUROC为0.87(95%CI 0.82-0.90)。作者结论认为该算法可支持PAD患者风险分层,但需进一步验证以用于临床实施。
要点
- 3年MALE发生于162例(29%)PAD患者。
- XGBoost模型预测3年MALE的测试集AUROC为0.88(95%CI 0.84-0.94)。
- 独立验证队列中XGBoost的AUROC为0.87(95%CI 0.82-0.90)。
核心结论
- 作者利用人口学、临床和新型生物标志物数据构建的机器学习算法能准确预测PAD患者3年MALE,可支持风险分层以进行额外血管评估和早期积极内科管理,从而改善结局,但模型用于临床实施前需进一步验证。
研究设计与样本
- 前瞻性招募的PAD患者队列,共569例,记录人口学/临床数据并测量基线血浆NT-proBNP、FABP3和FABP4浓度,随访3年。
- 采用10折交叉验证训练三种机器学习模型(随机森林、决策树和极端梯度提升[XGBoost])预测3年MALE,以受试者工作特征曲线下面积(AUROC)为主要模型评价指标。
主要发现
- 3年MALE见于162例患者(29%)。
- XGBoost为预测3年MALE表现最佳的模型,在测试集数据上AUROC=0.88(95%CI 0.84-0.94),灵敏度88%,特异度84%,阳性预测值83%,阴性预测值91%。
- 在独立的PAD患者验证队列中,XGBoost的AUROC为0.87(95%CI 0.82-0.90)。
- 3年MALE的10个最重要预测因素依次为:FABP3、FABP4、年龄、NT-proBNP、当前吸烟、糖尿病、高血压、血脂异常、冠状动脉疾病和性别。
临床怎么用
- 作者认为其算法可支持PAD患者风险分层,以便进行额外血管评估和早期积极内科管理,从而改善结局。
- 作者指出模型用于临床实施前需进一步验证。
局限性
- 原文在结论中写明:模型用于临床实施前需进一步验证(Further validation of our models for clinical implementation is warranted)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Prognostic tools for individuals with peripheral artery disease (PAD) remain limited. We developed prediction models for 3-year PAD-related major adverse limb events (MALE) using demographic, clinical, and biomarker data previously validated by our group. METHODS: We performed a prognostic study using a prospectively recruited cohort of patients with PAD (n = 569). Demographic/clinical data were recorded including sex, age, comorbidities, previous procedures, and medications. Plasma concentrations of three biomarkers (N-terminal pro-B-type natriuretic peptide [NT-proBNP], fatty acid binding protein 3 [FABP3], and FABP4) were measured at baseline. The cohort was followed for 3 years. MALE was the primary outcome (composite of open/endovascular vascular intervention or major amputation). We trained three machine learning models with 10-fold cross-validation using demographic, clinical, and biomarker data (random forest, decision trees, and Extreme Gradient Boosting [XGBoost]) to predict 3-year MALE in patients. Area under the receiver operating characteristic curve (AUROC) was the primary model evaluation metric. RESULTS: Three-year MALE was observed in 162 patients (29%). XGBoost was the top-performing predictive model for 3-year MALE, achieving the following performance metrics: AUROC = 0.88 (95% confidence interval [CI], 0.84-0.94); sensitivity, 88%; specificity, 84%; positive predictive value, 83%; and negative predictive value, 91% on test set data. On an independent validation cohort of patients with PAD, XGBoost attained an AUROC of 0.87 (95% CI, 0.82-0.90). The 10 most important predictors of 3-year MALE consisted of: (1) FABP3; (2) FABP4; (3) age; (4) NT-proBNP; (5) active smoking; (6) diabetes; (7) hypertension; (8) dyslipidemia; (9) coronary artery disease; and (10) sex. CONCLUSIONS: We built robust machine learning algorithms that accurately predict 3-year MALE in patients with PAD using demographic, clinical, and novel biomarker data. Our algorithms can support risk stratification of patients with PAD for additional vascular evaluation and early aggressive medical management, thereby improving outcomes. Further validation of our models for clinical implementation is warranted.
引用
- Li B, Nassereldine R, Zamzam A, et al. Development and evaluation of a prediction model for peripheral artery disease-related major adverse limb events using novel biomarker data. J Vasc Surg. 2024. PMID: 38599293. doi:10.1016/j.jvs.2024.03.450
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。